DDInter1083 DDInter1376
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lofexidine {u} (Compound) resembles {v} (Compound) Apraclonidine
Lofexidine {u} (Compound) binds {v} (Gene) ADRA2A
Lofexidine {u} (Compound) upregulates {v} (Gene) HMGA2
Lofexidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Lofexidine (Compound) resembles Apraclonidine (Compound)
Lofexidine (Compound) binds ADRA2A (Gene)
Lofexidine (Compound) upregulates HMGA2 (Gene)
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Lofexidine may lead to a major life threatening interaction when taken with Ribociclib
Lofexidine may lead to a major life threatening interaction when taken with Toremifene